Corsair Capital Management’s TransCode Therapeutics RNAZ Stock Holding History

Corsair Capital Management’s Portfolio RNAZ Stock Details RNAZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,429	Closed	-$19.8K	–	168
2025 Q1	$19.8K	Buy	+1,429	New	+$183K	0.01%	120

Other funds holding RNAZ

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SouthState Corp Winter Haven, Florida $2.4B AUM 23.05% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Corsair Capital Management's RNAZ Position: Q2 2025 in Review

Corsair Capital Management sold out of TransCode Therapeutics (RNAZ) in Q2 2025, closing a stake of 1,429 shares — an estimated $19.8K sold.

Corsair Capital Management first reported a position in RNAZ in Q1 2025 and held it in 1 quarter. The position peaked at $19.8K in Q1 2025. 9 funds tracked by Wall St. Rank hold RNAZ as of Q2 2025.

Corsair Capital Management reported no remaining TransCode Therapeutics position as of Q2 2025 after selling out during the quarter.
Corsair Capital Management sold 1,429 TransCode Therapeutics shares in Q2 2025, an estimated $19.8K.
Corsair Capital Management first reported a position in TransCode Therapeutics in Q1 2025 and held it in 1 quarter.
Corsair Capital Management's TransCode Therapeutics position peaked at $19.8K in Q1 2025.
9 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2025.

Based on Corsair Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.